You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

mechanistic target of rapamycin

Showing 1 - 25 of 9,630
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Muscle Atrophy, Age-Related Sarcopenia Trial in Derby (Rapamune (sirolimus) 1Mg Tablet, Unilateral resistance exercise training)

Recruiting
  • Muscle Atrophy
  • Age-Related Sarcopenia
  • Rapamune (sirolimus) 1Mg Tablet
  • Unilateral resistance exercise training
  • Derby, United Kingdom
    University of Nottingham School of Medicine
Jun 7, 2022

Insulin Sensitivity Trial in Copenhagen (other, procedure, drug)

Recruiting
  • Insulin Sensitivity
  • Exercise
  • +3 more
  • Copenhagen, Denmark
    University of Copenhagen
Jun 20, 2022

Dietary Protein Trial in Saint Louis (Dietary protein shake)

Active, not recruiting
  • Dietary Protein
  • Dietary protein shake
  • Saint Louis, Missouri
    Washington University
Jan 29, 2023

Coronary Artery Disease, Coronary Stenosis Trial (Rapamycin target eluting stent)

Not yet recruiting
  • Coronary Artery Disease
  • Coronary Stenosis
  • Rapamycin target eluting stent
  • (no location specified)
Oct 13, 2021

Coronary Artery Disease Trial in Worldwide (Microport Firehawk stent, 2nd generation DES (XIENCE family, Promus family,

Recruiting
  • Coronary Artery Disease
  • Microport Firehawk stent
  • 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)
  • Birmingham, Alabama
  • +56 more
Jul 25, 2022

Chronic Fatigue Syndrome, Myalgic Encephalomyelitis Trial in New York (NAC 900mg/day, NAC 3600mg/day, NAC 0mg/day (Placebo))

Recruiting
  • Chronic Fatigue Syndrome
  • Myalgic Encephalomyelitis
  • NAC 900mg/day
  • +2 more
  • New York, New York
    Weill Cornell Medicine
Jun 24, 2022

Activated PI3K-delta Syndrome, Immunodeficiency Primary Trial in Shanghai (Rapamycin)

Recruiting
  • Activated PI3K-delta Syndrome
  • Immunodeficiency Primary
  • Shanghai, Shanghai, China
  • +1 more
Mar 21, 2022

Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer Trial in Miami (AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor +

Not yet recruiting
  • Breast Cancer
  • +3 more
  • Miami, Florida
    University of Miami
Apr 12, 2023

Lymphangioleiomyomatosis, Tuberous Sclerosis Complex Trial in Boston ([11C]acetate)

Recruiting
  • Lymphangioleiomyomatosis
  • Tuberous Sclerosis Complex
  • Boston, Massachusetts
    Brigham and Women's Hospital
Jul 20, 2022

Soft-tissue Sarcoma Trial in Philadelphia (TAK-228)

Terminated
Has Results
  • Soft-tissue Sarcoma
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center
Sep 19, 2022

Lymphangioleiomyomatosis Trial in Spain (Loratadine, Placebo 10mg/day added to rapamycin for 12 months)

Recruiting
  • Lymphangioleiomyomatosis
  • Loratadine
  • Placebo 10mg/day added to rapamycin for 12 months
  • Hospitalet de Llobregat, Barcelona, Spain
  • +5 more
Jan 12, 2022

Peripheral Arterial Disease Trial (Rapamycin drug balloon angioplasty, Paclitaxel drug balloon angioplasty)

Not yet recruiting
  • Peripheral Arterial Disease
  • Rapamycin drug balloon angioplasty
  • Paclitaxel drug balloon angioplasty
  • (no location specified)
Aug 31, 2023

Vertebrobasilar Insufficiency Trial in Beijing (Drug-eluting stent)

Completed
  • Vertebrobasilar Insufficiency
  • Drug-eluting stent
  • Beijing, Beijing, China
    Beijing Tiantan Hospital
Jun 11, 2020

Castleman Disease, Castleman's Disease, Multicentric Trial in Little Rock, La Jolla, Philadelphia (Sirolimus)

Recruiting
  • Castleman Disease
  • Castleman's Disease, Multicentric
  • Little Rock, Arkansas
  • +3 more
Jan 6, 2023

Acne Vulgaris Trial (Topical Metformin Emulgel and salicylic acid, Insulin- Like growth factor (ILGF-1))

Not yet recruiting
  • Acne Vulgaris
  • Topical Metformin Emulgel and salicylic acid
  • Insulin- Like growth factor (ILGF-1)
  • (no location specified)
Sep 7, 2022

Solid Tumor, Adult, NSCLC, Advanced Cancer Trial (Adagrasib, nab-Sirolimus)

Not yet recruiting
  • Solid Tumor, Adult
  • +4 more
  • (no location specified)
Apr 24, 2023

Peripheral Arterial Disease Trial in Beijing (Percutaneous selective arteriography of peripheral arteries)

Not yet recruiting
  • Peripheral Arterial Disease
  • Percutaneous selective arteriography of peripheral arteries
  • Beijing, Beijing, China
    The First Medical Center of the General Hospital of the Chinese
Dec 14, 2022

Glioblastoma, Recurrent Glioblastoma Trial in San Francisco (RMC-5552)

Not yet recruiting
  • Glioblastoma
  • Recurrent Glioblastoma
  • San Francisco, California
    University of California, San Francisco
Nov 28, 2022

Aging, Insulin Resistance Trial in Madison (Everolimus 0.5 MG once per day, Everolimus 5 MG once per week, Placebo once per day)

Recruiting
  • Aging
  • Insulin Resistance
  • Everolimus 0.5 MG once per day
  • +3 more
  • Madison, Wisconsin
    University of Wisconsin-Madison
Apr 19, 2023

Asthma in Children, Obesity, Pediatric Obesity Trial in Durham (Pro2 - Low Dose - 40% of participant's MIP, Pro2 - High Dose -

Not yet recruiting
  • Asthma in Children
  • +3 more
  • Pro2 - Low Dose - 40% of participant's MIP
  • +2 more
  • Durham, North Carolina
  • +1 more
Jul 6, 2023

Atrophy, Disuse, Atrophy, Muscular Trial (Resistance Training Preconditioning, Control)

Not yet recruiting
  • Atrophy, Disuse
  • Atrophy, Muscular
  • Resistance Training Preconditioning
  • Control
  • (no location specified)
Feb 26, 2023

Aging Trial (Sirolimus)

Not yet recruiting
  • Aging
  • (no location specified)
Nov 3, 2022

Vitiligo Trial in Charleston (Rapamycin, Placebo)

Recruiting
  • Vitiligo
  • Charleston, South Carolina
    Medical University of South Carolina
Aug 2, 2022

Breast Cancer Trial in London ([18F]GE-226)

Recruiting
  • Breast Cancer
  • [18F]GE-226
  • London, United Kingdom
    Imperial College Healthcare NHS Trust
Jan 3, 2023

IgG4-related Disease Trial (Sirolimus)

Not yet recruiting
  • IgG4-related Disease
  • (no location specified)
Feb 25, 2023